Business Context and Reporting Period
MannKind Corporation (MNKD) is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases. The company commercializes Afrezza (inhaled insulin), Furoscix (subcutaneous furosemide), and V-Go (wearable insulin delivery device). It also manufactures Tyvaso DPI for United Therapeutics (UT) and receives royalties on its sales. This Form 10-Q covers the quarterly and six-month periods ended June 30, 2026.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $109,374 | $199,544 |
| Net (Loss) Income | $(19,032) | $(35,651) |
| Net (Loss) Income Per Share (Basic) | $(0.06) | $(0.12) |
| Operating Cash Flow | N/A | $(23,736) |
| Cash and Cash Equivalents | $52,929 | $52,929 |
| Total Debt (Principal) | $325,000 | $325,000 |
| Stockholders' Deficit | $(67,197) | $(67,197) |
Revenue Breakdown (Six Months 2026): Commercial product sales were $75.89 million (driven by Furoscix), Collaborations and services were $58.54 million, and Royalties were $65.12 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 43% year-over-year for the quarter and 29% for the six-month period. This was primarily driven by the inclusion of Furoscix revenue following the October 2025 acquisition of scPharmaceuticals Inc. (scPharma).
- Profitability Decline: The company reported a net loss of $19.0 million for the quarter, compared to a net income of $0.7 million in the prior year quarter. The six-month net loss was $35.7 million versus net income of $13.8 million in the prior year.
- Expense Increases: Selling, general, and administrative (SG&A) expenses surged 84% for the quarter and 98% for the six months, largely due to Furoscix launch costs and expanded field teams. Research and development (R&D) expenses increased 32% and 43% respectively, driven by Furoscix ReadyFlow development and MNKD-201 clinical trials.
- Interest Expense: Interest expense increased significantly due to the new $325 million Blackstone term loan facility drawn in late 2025 and the achievement of an Afrezza sales milestone triggering interest recognition.
- Foreign Currency: The company recorded a gain of $0.5 million for the quarter and $1.8 million for the six months on foreign currency transactions, reversing losses in the prior year periods.
Guidance, Outlook, Risks, and Unusual Items
- Subsequent Event (Private Placement): On July 24, 2026, the company completed a private placement raising approximately $50.0 million. Proceeds are intended to fund a $44.8 million Contingent Value Right (CVR) payment triggered by the FDA approval of Furoscix ReadyFlow on July 23, 2026.
- Debt Obligations: The company holds a $325 million Blackstone term loan maturing in 2030 with an effective interest rate of 9.12%. It also has significant contingent liabilities, including the CVR obligation and a $45.0 million Milestone Rights liability.
- Liquidity: As of June 30, 2026, the company held $111.1 million in cash, cash equivalents, and investments. Management believes resources are sufficient to fund operations for at least the next 12 months.
- Risks: Key risks include the commercial success of Furoscix, reliance on United Therapeutics for Tyvaso DPI royalties (which faces competition from UT's own pipeline product Tresmi), supply chain disruptions (particularly for V-Go manufactured in China), and the ability to service high levels of debt.
- Unusual Items: The financial results include a $7.8 million non-cash expense related to the remeasurement of the fair value of the contingent consideration liability from the scPharma acquisition.
Investor Verification Checklist
- CVR Payment Execution: Verify the successful disbursement of the $44.8 million CVR payment to scPharma shareholders using the proceeds from the July 2026 private placement.
- Furoscix Commercialization: Monitor early sales data and market adoption rates for Furoscix and the newly approved Furoscix ReadyFlow to assess if revenue projections are being met.
- Debt Covenant Compliance: Confirm continued compliance with the Blackstone Credit Facility liquidity covenant (minimum $40 million unrestricted cash) and interest coverage ratios.
- United Therapeutics Strategy: Assess any shifts in United Therapeutics' commercial focus from Tyvaso DPI to its new product Tresmi, which could materially impact MannKind's royalty revenue.
- Insulin Supply Commitments: Review the status of the long-term insulin purchase commitments with Amphastar and the associated recognized loss on purchase commitments ($64.1 million).